Clinical Trials Logo

Mantle Cell Lymphoma Recurrent clinical trials

View clinical trials related to Mantle Cell Lymphoma Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT05645744 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Start date: September 29, 2021
Phase:
Study type: Observational

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

NCT ID: NCT05360238 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Start date: May 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

NCT ID: NCT04234061 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma Recurrent

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

TARMAC
Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.

NCT ID: NCT02086591 Recruiting - Clinical trials for Small Lymphocytic Lymphoma

A Phase II Study of Doxycycline in Relapsed NHL

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).

NCT ID: NCT01322776 Recruiting - Clinical trials for Mantle Cell Lymphoma Recurrent

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Start date: March 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, single arm, open-label, prospective IIS study, which will enroll 40 recurrent MCL patients.The aim is to evaluate the efficacy and safety of bortezomib, fludarabine and cyclophosphamide treatment and also analyze the relationship between NF-kB activity and efficacy of bortezomib treatment and whether NF-kB activity can predict MCL progression.